Post-earnings recap
Reported
Tue, Feb 24, 2009
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Alnylam Pharmaceuticals reported a loss that was worse than expected, with an EPS of $-0.23. Despite this miss, the stock rose by 5.53%, indicating that investors may have reacted positively to other aspects of the company's performance or future prospects, although specific details were not provided in the earnings call.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.23 | N/A | -53.33% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based solely on numerical results.